Wealth Enhancement Advisory Services
REGN icon

Wealth Enhancement Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9M Sell
33,880
-3,716
-10% -$2.53M 0.03% 509
2026
Q1 		$21M Buy
37,596
+15,233
+68% +$11.7M 0.04% 378
2025
Q4 		$17.5M Buy
22,363
+4,778
+27% +$3.24M 0.02% 514
2025
Q3 		$10.3M Buy
17,585
+7,923
+82% +$4.48M 0.02% 648
2025
Q2 		$5.29M Sell
9,662
-24,083
-71% -$13.4M 0.01% 874
2025
Q1 		$21.4M Sell
33,745
-12,246
-27% -$8.42M 0.04% 378
2024
Q4 		$32.8M Buy
45,991
+14,997
+48% +$12.6M 0.06% 278
2024
Q3 		$32.6M Buy
30,994
+7,360
+31% +$8.19M 0.07% 267
2024
Q2 		$24.8M Buy
23,634
+483
+2% +$468K 0.06% 292
2024
Q1 		$22.3M Buy
23,151
+2,412
+12% +$2.29M 0.06% 301
2023
Q4 		$18.2M Buy
20,739
+2,620
+14% +$2.16M 0.05% 321
2023
Q3 		$14.9M Buy
18,119
+13,248
+272% +$10.4M 0.05% 325
2023
Q2 		$3.5M Buy
4,871
+488
+11% +$376K 0.04% 153
2023
Q1 		$3.6M Buy
4,383
+235
+6% +$177K 0.04% 160
2022
Q4 		$3.06M Buy
+4,148
New +$3.06M 0.04% 150
2019
Q3 		– Sell
-5,173
Closed -$1.58M – 234
2019
Q2 		$1.58M Buy
5,173
+2,645
+105% +$881K 0.07% 112
2019
Q1 		$870K Buy
+2,528
New +$1.04M 0.05% 149
2017
Q2 		– Sell
-3,001
Closed -$1.16M – 182
2017
Q1 		$1.16M Buy
3,001
+916
+44% +$340K 0.12% 82
2016
Q4 		$766K Sell
2,085
-498
-19% -$189K 0.09% 109
2016
Q3 		$1.01M Buy
+2,583
New +$1.04M 0.15% 85

Other funds holding REGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM

Wealth Enhancement Advisory Services's REGN Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Regeneron Pharmaceuticals (REGN) stake by 9.9% in Q2 2026, selling an estimated $2.53M and leaving 33,880 shares worth $15.9M. The position accounts for 0.03% of the portfolio, ranked #509.

Wealth Enhancement Advisory Services first reported a position in REGN in Q3 2016 and has held it in 20 quarters since. The position peaked at $32.8M in Q4 2024. 210 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Wealth Enhancement Advisory Services held 33,880 shares of Regeneron Pharmaceuticals worth $15.9M as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 3,716 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.53M.
  • Regeneron Pharmaceuticals made up 0.03% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #509 holding.
  • Wealth Enhancement Advisory Services first reported a position in Regeneron Pharmaceuticals in Q3 2016 and has held it in 20 quarters since.
  • Wealth Enhancement Advisory Services's Regeneron Pharmaceuticals position peaked at $32.8M in Q4 2024.
  • 210 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.